To Evaluate the Effects of EryDex in Patients With A-T
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is an international, multi-center, randomized, prospective, double-blind,
placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone
sodium phosphate [DSP] in autologous erythrocytes), administered by intravenous (IV) infusion
once every 28 days, on neurological symptoms of patients with Ataxia Telangectasia (A-T).